CA2797787C - Metabolic biomarkers of autism - Google Patents

Metabolic biomarkers of autism Download PDF

Info

Publication number
CA2797787C
CA2797787C CA2797787A CA2797787A CA2797787C CA 2797787 C CA2797787 C CA 2797787C CA 2797787 A CA2797787 A CA 2797787A CA 2797787 A CA2797787 A CA 2797787A CA 2797787 C CA2797787 C CA 2797787C
Authority
CA
Canada
Prior art keywords
metabolites
autism
autistic
cellular metabolites
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2797787A
Other languages
English (en)
French (fr)
Other versions
CA2797787A1 (en
Inventor
Gabriela Gebrin Cezar
Alan M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Stemina Biomarker Discovery Inc
Original Assignee
Wisconsin Alumni Research Foundation
Stemina Biomarker Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation, Stemina Biomarker Discovery Inc filed Critical Wisconsin Alumni Research Foundation
Publication of CA2797787A1 publication Critical patent/CA2797787A1/en
Application granted granted Critical
Publication of CA2797787C publication Critical patent/CA2797787C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2797787A 2010-04-29 2011-04-29 Metabolic biomarkers of autism Active CA2797787C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32951510P 2010-04-29 2010-04-29
US61/329,515 2010-04-29
PCT/US2011/034654 WO2011139914A1 (en) 2010-04-29 2011-04-29 Metabolic biomarkers of autism

Publications (2)

Publication Number Publication Date
CA2797787A1 CA2797787A1 (en) 2011-11-10
CA2797787C true CA2797787C (en) 2019-07-09

Family

ID=44533446

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797787A Active CA2797787C (en) 2010-04-29 2011-04-29 Metabolic biomarkers of autism

Country Status (6)

Country Link
US (2) US9547013B2 (enExample)
EP (1) EP2564194B1 (enExample)
JP (2) JP6021187B2 (enExample)
AU (2) AU2011248464B2 (enExample)
CA (1) CA2797787C (enExample)
WO (1) WO2011139914A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101322695B1 (ko) * 2010-08-25 2013-10-25 주식회사 엘지화학 케이블형 이차전지
WO2012048152A2 (en) 2010-10-07 2012-04-12 Mazmanian Sarkis K Probiotic therapies for autism
CN114949001A (zh) * 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
WO2015027116A1 (en) * 2013-08-21 2015-02-26 The Regents Of The University Of California Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system
CN106537145B (zh) * 2014-04-08 2020-08-25 麦特博隆股份有限公司 用于疾病诊断和健康评估的个体受试者的小分子生物化学特征分析
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
US11282688B2 (en) 2015-03-06 2022-03-22 Micromass Uk Limited Spectrometric analysis of microbes
EP3570315B1 (en) 2015-03-06 2024-01-31 Micromass UK Limited Rapid evaporative ionisation mass spectrometry ("reims") and desorption electrospray ionisation mass spectrometry ("desi-ms") analysis of biopsy samples
US11289320B2 (en) 2015-03-06 2022-03-29 Micromass Uk Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
WO2016142674A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Cell population analysis
CA2981085A1 (en) * 2015-03-06 2016-09-15 Micromass Uk Limited Spectrometric analysis
JP6421742B2 (ja) 2015-11-27 2018-11-14 株式会社デンソー 車両制御装置
WO2017178833A1 (en) 2016-04-14 2017-10-19 Micromass Uk Limited Spectrometric analysis of plants
US11707493B2 (en) 2016-05-23 2023-07-25 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
CN107064340A (zh) * 2017-03-13 2017-08-18 瀚盟测试科技(天津)有限公司 一种检测茶叶中gaba含量的方法
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
GB201802116D0 (en) 2018-02-09 2018-03-28 Univ Warwick Methods for diagnosing an autistic spectrum disorder
CN109030665A (zh) * 2018-10-08 2018-12-18 黑龙江大学 亲水性液相色谱串联质谱法测定红甜菜中甜菜碱含量的检测方法
US12474327B2 (en) 2018-11-06 2025-11-18 Stalicla Sa Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1
EP4012414A1 (en) 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113960200B (zh) * 2021-10-19 2023-06-20 首都医科大学附属北京儿童医院 代谢标志物在诊断儿童adhd合并抽动障碍中的应用
CN114705775B (zh) * 2022-03-31 2023-09-12 广东省结核病控制中心 一种肺结核评价的血清代谢标志物及其应用
CN115326953A (zh) * 2022-08-02 2022-11-11 云谱康(大连)生物科技有限公司 一种代谢物组合及应用和检测试剂盒与使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
CA2273683A1 (en) * 1998-06-15 1999-12-15 Ortho-Clinical Diagnostics, Inc. Diagnostic markers for human disorders
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
WO2006121952A2 (en) 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
JP5421767B2 (ja) * 2006-04-10 2014-02-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ヒト胚性幹細胞を使用して薬学的化合物および他の化学物質の毒性を評価するための試薬および方法
US8670941B2 (en) * 2006-08-18 2014-03-11 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing Alzheimer's disease
AU2008280806B2 (en) * 2007-07-26 2014-12-11 Phenomenome Discoveries Inc. Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
JP5680964B2 (ja) * 2007-10-04 2015-03-04 ザ ホスピタル フォー シック チルドレン 自閉症スペクトラム障害のためのバイオマーカー
EP2279417B1 (en) * 2008-05-28 2016-07-20 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof

Also Published As

Publication number Publication date
AU2011248464B2 (en) 2016-08-11
JP2013525801A (ja) 2013-06-20
AU2016204969B2 (en) 2018-05-17
CA2797787A1 (en) 2011-11-10
US20120190055A1 (en) 2012-07-26
JP2015231392A (ja) 2015-12-24
EP2564194A1 (en) 2013-03-06
US9547013B2 (en) 2017-01-17
JP6021187B2 (ja) 2016-11-09
US10330688B2 (en) 2019-06-25
EP2564194B1 (en) 2019-07-10
AU2011248464A1 (en) 2012-11-22
AU2016204969A1 (en) 2016-08-04
US20170192019A1 (en) 2017-07-06
WO2011139914A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
US10330688B2 (en) Metabolic biomarkers of autism
Roede et al. Serum metabolomics of slow vs. rapid motor progression Parkinson’s disease: a pilot study
Gonzalez-Dominguez et al. Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry
US11268966B2 (en) Biomarkers of autism spectrum disorder
Sandlers The future perspective: metabolomics in laboratory medicine for inborn errors of metabolism
Cheng et al. Metabolic disturbances in plasma as biomarkers for Huntington's disease
German et al. Serum biomarkers for Alzheimer's disease: proteomic discovery
US20050101023A1 (en) Methods for diagnosing urinary tract and prostatic disorders
Li et al. Urinary metabolomics revealed arsenic exposure related to metabolic alterations in general Chinese pregnant women
KR20140043782A (ko) 알츠하이머병의 증가된 위험도를 진단하는 방법
CN102339356B (zh) 应用代谢组学技术评价与预测药物毒性和药效的方法
WO2010005387A1 (en) New method and biomarkers for the diagnosis of multiple sclerosis
LeWitt et al. Diagnostic metabolomic profiling of Parkinson's disease biospecimens
CN111562338A (zh) 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
CN116678974A (zh) 一种阿尔茨海默症血浆代谢标志物的筛选方法、血浆代谢标志物及应用
Lin et al. The identification of a potential plasma metabolite marker for Alzheimer’s disease by LC-MS untargeted metabolomics
Yang et al. Serum metabolic profiling study of endometriosis by using wooden-tip electrospray ionization mass spectrometry
CN109946411B (zh) 用于胸椎黄韧带骨化诊断的生物标记物及其筛选方法
Berezhnoy et al. Application of IVDr NMR spectroscopy to stratify Parkinson’s disease with absolute quantitation of blood serum metabolites and lipoproteins
CN104297442B (zh) 内源性小分子物质在快速检测早期心脏毒性方面的应用
WO2015061317A1 (en) Biomarkers for memory loss
CN115754260A (zh) 一种阿尔兹海默症粪便代谢标志物及其筛选方法和应用
CN109946467A (zh) 一种用于胸椎黄韧带骨化诊断的生物标记物
CN113552228A (zh) 一组用于诊断儿童毛细支气管炎的联合标志物及其应用和检测试剂盒
CN112305123B (zh) 小分子物质在动脉粥样硬化性脑梗死中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160412

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260610